Summary
We present a rare case of a patient with chronic eosinophilic leukemia, who did not develope the well known organ involvements of the heart, lungs, the skin or nervous system, but who suffered form atypical thrombotic complications including a life threatening sinovenous thrombosis. His disease showed a rapid response to a very low dose of imatinib an the complete remission of a complex cytogenetic abnormality.
References
Hellmich B, Holl-Ulrich K Gross W. Hypereosinophiles Syndrom: Aktueller Stand der Diagnostik und Therapie. Dtsch Med Wochenschr, 132: 1892–1896, 2007
Roufossue F, Goldman M, Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Diseases, 2: 37, 2007 (DOI: 10.1186/1750-1172-2-37)
Roufosse F, Cogan A, Goldman M. Recent advances in the pathogenesis and management of hypereosinopholic syndromes. Allergy, 59: 673–689, 2004
Cools J, DeAngelo D, Gotlib J, et al. A tyrosin kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med, 348: 1201–1214, 2003
Cross NCP, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia, 16: 1207–1212, 2002
Narayan S, Ezughah F, Standen G, et al. Idiopathic hypereosinophilic syndrome associated with cutaneous infarction and deep venous thrombosis. Br J Dermatol, 148: 817–820, 2003
Schulman H, Hertzog L, Zirkin H, Hertzanu Y. Cerebral sinovenous thrombosis in the idiopathic hypereosinophilic syndrome in childhood. Pediatr Radiol, 29: 595–597, 1999
Cortes J, Ault P, Koller Ch, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood, 101: 4714–4716, 2003
Onitilo A, Kio E, Singh A, Lazarchick J. Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction. Leuk Lymphoma, 46(11): 1667–1670, 2005
Yamada O, Kitahara K, Imamura K, Ozasa H, Okada M, Mizoguchi H. Clinical and cytogenetic remission induced by interferon-alpha in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation. Am J Haematol, 58(2): 137–141, 1998
Rothenberg M, Gleich G, Roufosse F, Rossenwasser L, Weller P. Steroid sparing effect of anti-IL5 antibody (mepolizumab) therapy in patients with HES: a multicenter, randomized, double-blind, placebo-controlled trial. Blood, 108: 373, 2006
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zabernigg, A., Erdel, M., Schranzhofer, R. et al. Complete cytogenetic remission in a patient with FIP1L1-PDGFRA fusion negative chronic eosinophilic leukemia associated with atypical thrombotic events. memo 1, 39–41 (2008). https://doi.org/10.1007/s12254-008-0010-9
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s12254-008-0010-9